The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected ...

Pharmaceutical innovation has had a huge impact on society by extending and improving the quality of life, but this extends to a larger healthy working population and improvements in gross domestic ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced gadolinium dose, supporting safer repeat use in adults and pediatric patients.

Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years ...

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through ...

The key to improving SFE in 2025 lies in fundamentally reorienting measurement from representative activities to the value ...

The companies are working together to make it easier for companies to offer health plans that include these medications.